Expressions of erythropoietin and CD105 in glioma tissues in patients with gliomas and their meanings

XU Shu; YUE Zhi-jian; ZHOU Xiao-ping; WANG Jian-jun; WANG Lai-xing; ZHANG Yu-hui; LIU Jian-min

doi:10.13798/j.issn.1009-153X.2018.05.003

Abstract：Objective To explore the expressions of erythropoietin(EPO)and CD105 in human glioma tissues and their meanings. Methods The expressions of EPO and CD105 in 152 cases of gliomas tissues including 7 cases of WHO gradeⅠ,29 cases of WHO grade Ⅱ, 68 cases of WHO grade Ⅲ and 48 cases of WHO grade Ⅳ and 20 cases of normal brain tissue were determined by immunohistochemiscal technique.The expression of EPO mRNA in 17 cases of gliomas including 6 cases of WHO gradeⅡand 11 cases of WHO gradeⅢ~Ⅳ and 5 cases of normal brain tissue were detected by real time PCR. The relationship of EPO expression with survival rate was analyzed by survival curve.Results The level of EPO expression in the glioma tissues were significantly higher than that in the normal brain tissues(P<0.01),and was positively correlated with the WHO grade of the tumor(rs=0.368,P<0.01).The CD105 expression level was significantly higher in the positive EPO expression group than that in the negative EPO expression group(P<0.05). The level of EPO mRNA expression was significantly higher in the WHO gradeⅡglioma tissues than those of normal brain tissues(P<0.01)and WHO gradeⅢ~Ⅳgliomas tissues(P<0.05).The survival curve analysis showed that the survival time was significantly longer in the patients with high WHO grade gliomas in which EPO was strongly expressed than that in the patients with high WHO grade gliomas in which EPO was weakly expressed(P<0.05).Conclusions Our results suggest that the level of EPO expression in the tumorous tissue is positively related to WHO grade and neovascularization of glioma.The level of EPO mRNA expression in WHO gradeⅡglioma has been upregulated in DNA transcription.The patients with WHOⅢ~Ⅳgliomas in whom EPO protein is strongly expressed survive longer compared to the patients with WHOⅢ~Ⅳgliomas in whom EPO is weakly expressed.